Cargando…

Levoketoconazole in the Treatment of Patients With Cushing’s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study

BACKGROUND: Cushing’s syndrome (CS) is associated with numerous comorbidities, including diabetes mellitus (DM). Levoketoconazole, an orally administered ketoconazole stereoisomer, is in clinical trials for the treatment of CS. METHODS: SONICS, a prospective, open-label, phase 3 study in adults with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pivonello, Rosario, Elenkova, Atanaska, Fleseriu, Maria, Feelders, Richard A., Witek, Przemyslaw, Greenman, Yona, Geer, Eliza B., Perotti, Paola, Saiegh, Leonard, Cohen, Fredric, Arnaldi, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059833/ https://www.ncbi.nlm.nih.gov/pubmed/33897615 http://dx.doi.org/10.3389/fendo.2021.595894

Ejemplares similares

SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM)
por: Fleseriu, Maria, et al.
Publicado: (2019)

Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
por: Geer, Eliza B., et al.
Publicado: (2020)

Correction to: Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
por: Geer, Eliza B., et al.
Publicado: (2020)

Levoketoconazole treatment in endogenous Cushing’s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes
por: Fleseriu, Maria, et al.
Publicado: (2022)

Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)
por: Pivonello, Rosario, et al.
Publicado: (2022)

MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study
por: Zacharieva, Sabina Z, et al.
Publicado: (2020)

Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study
por: Zacharieva, Sabina, et al.
Publicado: (2021)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease
por: Newell-Price, John, et al.
Publicado: (2019)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2)
por: Fleseriu, Maria, et al.
Publicado: (2022)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension
por: Fleseriu, Maria, et al.
Publicado: (2022)

Cushing’s disease: adrenal steroidogenesis inhibitors
por: Pivonello, Rosario, et al.
Publicado: (2022)

Neuropsychiatric disorders in Cushing's syndrome
por: Pivonello, Rosario, et al.
Publicado: (2015)

Comorbidities in Cushing’s disease
por: Sharma, S. T., et al.
Publicado: (2015)

The dopaminergic control of Cushing’s syndrome
por: Pivonello, R., et al.
Publicado: (2022)

New treatment guidelines on Cushing's disease
por: Arnaldi, Giorgio, et al.
Publicado: (2009)

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”
por: Pivonello, Rosario, et al.
Publicado: (2019)

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study
por: Findling, James W., et al.
Publicado: (2016)

Recent advances in the medical treatment of Cushing’s disease
por: Fleseriu, Maria
Publicado: (2014)

Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials
por: Pivonello, Rosario, et al.
Publicado: (2020)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

Causes and Metabolic Consequences of Gynecomastia in Adult Patients
por: Robeva, Ralitsa, et al.
Publicado: (2019)

Medical management of Cushing’s disease: what is the future?
por: Fleseriu, Maria, et al.
Publicado: (2012)

Pituitary-Directed Therapies for Cushing’s Disease
por: Langlois, Fabienne, et al.
Publicado: (2018)

Randomized Trial of Osilodrostat for the Treatment of Cushing Disease
por: Gadelha, Mônica, et al.
Publicado: (2022)

THU040 Different Patient Versus Provider Perspectives On Living With Cushing’s Disease
por: Halstrom, Amanda, et al.
Publicado: (2023)

Cushing’s syndrome: epidemiology and developments in disease management
por: Sharma, Susmeeta T, et al.
Publicado: (2015)

Approach to patients with pseudo-Cushing’s states
por: Scaroni, Carla, et al.
Publicado: (2019)

Medical treatment of Cushing’s disease with concurrent diabetes mellitus
por: Mehlich, Anna, et al.
Publicado: (2023)

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
por: Pivonello, Rosario, et al.
Publicado: (2021)

Salivary Cortisol in the Diagnosis of Cushing Syndrome, Always More Than One!
por: Fleseriu, Maria
Publicado: (2020)

Hypercoagulability in Cushing’s syndrome: incidence, pathogenesis and need for thromboprophylaxis protocols
por: Feelders, Richard A., et al.
Publicado: (2022)

Update on medical treatment for Cushing’s disease
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
por: Pivonello, Rosario, et al.
Publicado: (2022)

Perioperative Management of a Patient With Cushing Disease
por: Varlamov, Elena V, et al.
Publicado: (2022)

THU035 Impact Of Surgery Or Medical Treatment With The Selective Glucocorticoid Receptor Modulator Relacorilant On Hypercoagulopathy In Patients With Cushing Syndrome
por: Simeoli, Chiara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_srficmuki212sa7okncna2njor